The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Serum Visfatin Increases With Progressive β-Cell Deterioration
Open accessAbstract
Visfatin has shown to be increased in type 2 diabetes but to be unrelated to insulin sensitivity. We hypothesized that visfatin is associated with insulin secretion in humans. To this aim, a cross-sectional study was conducted in 118 nondiabetic men and 64 (35 men and 29 women) type 2 diabetic patients. Type 1 diabetic patients with long-standing disease (n = 58; 31 men and 27 women) were also studied. In nondiabetic subjects, circulating visfatin (enzyme immunoassay) was independently associated with insulin secretion (acute insulin response to glucose [AIRg] from intravenous glucose tolerance tests) but not with insulin sensitivity (Si) or other metabolic or anthropometric parameters, and AIRg alone explained 8% of visfatin variance (β = −0.29, P = 0.001). Circulating visfatin was increased in type 2 diabetes (mean 18 [95% CI 16–21] vs. 15 ng/ml [13–17] for type 2 diabetic and nondiabetic subjects, respectively; P = 0.017, adjusted for sex, age, and BMI), although this association was largely attenuated after accounting for HbA1c (A1C). Finally, circulating visfatin was found to be increased in patients with long-standing type 1 diabetes, even after adjusting for A1C values (37 ng/ml [34–40]; P < 0.0001, adjusted for sex, age, BMI, and A1C compared with either type 2 diabetic or nondiabetic subjects). In summary, circulating visfatin is increased with progressive β-cell deterioration. The study of the regulation and role of visfatin in diabetes merits further consideration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin
Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Matsuki, Y., Murakami, M., Ichisaka, T., Murakami, H., et al. (2005) · Science · doi:10.1126/science.1097243 · Cited by 1,906
RetractedThe Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
The release of the adipocytokine visfatin is regulated by glucose and insulin
Haider, D. G., Schaller, G., Kapiotis, S., Maier, C., Luger, A., & Wolzt, M. (2006) · Diabetologia · doi:10.1007/s00125-006-0303-7 · Cited by 258
Cited by
Adipokines: The missing link between insulin resistance and obesity
Antuna-Puente, B., Feve, B., Fellahi, S., & Bastard, J.-P. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.09.004 · Cited by 737
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Garten, A., Schuster, S., Penke, M., Gorski, T., de Giorgis, T., & Kiess, W. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.117 · Cited by 708
Obesity: A Chronic Low-Grade Inflammation and Its Markers
Khanna, D., Khanna, S., Khanna, P., Kahar, P., & Patel, B. M. (2022) · Cureus · doi:10.7759/cureus.22711 · Cited by 492
Chang, Y., Chang, D., Lin, K., Shin, S., & Lee, Y. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1201 · Cited by 356
Cardiometabolic Aspects of the Polycystic Ovary Syndrome
Randeva, H. S., Tan, B. K., Weickert, M. O., Lois, K., Nestler, J. E., Sattar, N., & Lehnert, H. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1003 · Cited by 322
Metadata
- Authors
- López-Bermejo, A., Chico-Julià, B., Fernàndez-Balsells, M., Recasens, M., Esteve, E., Casamitjana, R., Ricart, W., & Fernández-Real, J.-M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2006-10-01
- Volume
- 55
- Issue
- 10
- Pages
- 2871-2875
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2152425714
- Cited by
- 216
- References
- 3
- FWCI
- 14.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.